Screener
Eikon Therapeutics, Inc. EIKN Investing Cash Flow
Investing Cash Flow at other companies
Other financials
Where this comes from
Reported directly by Eikon Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInInvestingActivities.
The source filing: Eikon Therapeutics, Inc.’s 10-Q, filed May 11, 2026.
- Filed
- May 11, 2026, 4:13 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-216791
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Purchase of property and equipment | (262) | (22,358) |
| Purchase of marketable securities | (306,955) | (252,496) |
| Proceeds from maturities of marketable securities | 104,000 | 61,000 |
| Net cash used in investing activities | (203,217) | (213,854) |
| Financing Activities | ||
| Proceeds from issuance of common stock under stock plans | 277 | 21 |
| Proceeds from issuance of redeemable convertible preferred stock, net of issuance costs | — | 350,213 |
| Proceeds from initial public offering, net of issuance costs | 349,031 | — |
Item 1. Condensed Financial Statements (Unaudited).
FAQ
- What is Eikon Therapeutics, Inc.'s investing cash flow?
- Eikon Therapeutics, Inc. (EIKN) reported investing cash flow of -$203.22M in Q1 2026.
- What does investing cash flow mean?
- Total net cash provided by or used in investing activities — capex, acquisitions, investment purchases/sales, and other investing items.
Ask your AI about Eikon Therapeutics, Inc.'s investing cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude